Xeris Biopharma (XERS) Revenue & Revenue Breakdown
Xeris Biopharma Revenue Highlights
Latest Revenue (Y)
$163.91M
Latest Revenue (Q)
$52.86M
Main Segment (Y)
Product
Xeris Biopharma Revenue by Period
Xeris Biopharma Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $163.91M | 48.68% |
2022-12-31 | $110.25M | - |
2021-12-31 | $110.25M | 122.32% |
2020-12-31 | $49.59M | 146.04% |
2019-12-31 | $20.16M | 717.65% |
2018-12-31 | $2.46M | 58.42% |
2017-12-31 | $1.56M | 44.74% |
2016-12-31 | $1.07M | - |
Xeris Biopharma Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $52.86M | 9.98% |
2024-06-30 | $48.06M | 18.28% |
2024-03-31 | $40.64M | -8.45% |
2023-12-31 | $44.39M | -8.13% |
2023-09-30 | $48.32M | 27.13% |
2023-06-30 | $38.01M | 14.50% |
2023-03-31 | $33.20M | -12.66% |
2022-12-31 | $38.01M | 27.87% |
2022-09-30 | $29.73M | 17.46% |
2022-06-30 | $25.31M | 14.65% |
2022-03-31 | $22.07M | 3.01% |
2021-12-31 | $21.43M | 94.19% |
2021-09-30 | $11.04M | 23.91% |
2021-06-30 | $8.91M | 10.62% |
2021-03-31 | $8.05M | 13.57% |
2020-12-31 | $7.09M | -24.97% |
2020-09-30 | $9.45M | 366.11% |
2020-06-30 | $2.03M | 13.37% |
2020-03-31 | $1.79M | -4.08% |
2019-12-31 | $1.86M | 477.09% |
2019-09-30 | $323.00K | 0.94% |
2019-06-30 | $320.00K | 29.03% |
2019-03-31 | $248.00K | -69.04% |
2018-12-31 | $801.00K | 37.63% |
2018-09-30 | $582.00K | -28.94% |
2018-06-30 | $819.00K | 211.41% |
2018-03-31 | $263.00K | -43.68% |
2017-12-31 | $467.00K | 174.71% |
2017-09-30 | $170.00K | -69.91% |
2017-06-30 | $565.00K | 59.60% |
2017-03-31 | $354.00K | - |
Xeris Biopharma Revenue Breakdown
Xeris Biopharma Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 |
---|---|---|
Product | $153.36M | $109.26M |
Keveyis | $56.77M | $49.31M |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 |
---|---|---|---|---|---|---|---|---|---|
Keveyis | $12.19M | $13.09M | $40.91M | $15.87M | $14.09M | $12.76M | $13.80M | $13.37M | $12.81M |
Product | $52.86M | $40.26M | $111.67M | $41.70M | $36.89M | $32.27M | $32.54M | $29.55M | $25.26M |
Latest
Xeris Biopharma Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
XERS | Xeris Biopharma | $163.91M | $52.86M |
MCRB | Seres Therapeutics | $126.33M | - |
CDTX | Cidara Therapeutics | $63.91M | - |
HOOK | HOOKIPA Pharma | $20.13M | - |
MREO | Mereo BioPharma Group | $10.00M | - |
IBRX | ImmunityBio | $622.00K | $1.05M |
XFOR | X4 Pharmaceuticals | - | $560.00K |
PDSB | PDS Bio | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
INZY | Inozyme Pharma | - | - |
ELEV | Elevation Oncology | - | - |
TERN | Terns Pharmaceuticals | - | - |
HEPA | Hepion Pharmaceuticals | - | - |
EFTR | eFFECTOR Therapeutics | - | - |